ESR1 and breast carcinoma: CDK4/6 is a key regulator of the cell cycle, and inhibition of its pathway is slowly becoming a possible therapeutic strategy for this type of breast cancer, with the opportunity to achieve blockade at the intersection of the ER and HER2 dual pathways (31).